• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌脑转移临床实践中的微环境与免疫治疗进展

Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis.

作者信息

Xie Mengqing, Su Chunxia

机构信息

Department of Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, School of Medicine, Tongji University, Shanghai, China.

出版信息

Front Oncol. 2023 Jan 24;12:1006284. doi: 10.3389/fonc.2022.1006284. eCollection 2022.

DOI:10.3389/fonc.2022.1006284
PMID:36761422
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9902941/
Abstract

One of the most frequent distant metastases of lung cancer occurs in the brain. The average natural survival duration for patients with lung cancer who have brain metastases is about 1 to 2 months. Knowledge about brain metastases is currently restricted since they are more difficult to acquire than other metastases. This review begins with an analysis of the immune microenvironment of brain metastases; focuses primarily on the functions of microglia, astrocytes, neurons, and tumor-infiltrating lymphocytes in the microenvironment of brain metastases; and offers an atlas of the immune microenvironment of brain metastases involving significant cells. In an effort to give researchers new research ideas, the study also briefly covers how immunotherapy for non-small cell lung cancer with brain metastases is currently faring.

摘要

肺癌最常见的远处转移之一发生在脑部。发生脑转移的肺癌患者的平均自然生存时间约为1至2个月。目前关于脑转移的知识有限,因为获取脑转移相关信息比获取其他转移灶的信息更难。本综述首先分析脑转移的免疫微环境;主要关注小胶质细胞、星形胶质细胞、神经元和肿瘤浸润淋巴细胞在脑转移微环境中的功能;并提供涉及重要细胞的脑转移免疫微环境图谱。为了给研究人员提供新的研究思路,该研究还简要介绍了目前非小细胞肺癌脑转移免疫治疗的进展情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/530d/9902941/c01b316b74c8/fonc-12-1006284-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/530d/9902941/c01b316b74c8/fonc-12-1006284-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/530d/9902941/c01b316b74c8/fonc-12-1006284-g001.jpg

相似文献

1
Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis.非小细胞肺癌脑转移临床实践中的微环境与免疫治疗进展
Front Oncol. 2023 Jan 24;12:1006284. doi: 10.3389/fonc.2022.1006284. eCollection 2022.
2
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.非小细胞肺癌脑转移患者的免疫治疗。了解脑肿瘤微环境并剖析临床免疫检查点阻断治疗的结果。
Cancer Treat Rev. 2020 Sep;89:102067. doi: 10.1016/j.ctrv.2020.102067. Epub 2020 Jul 7.
3
[Research progress in immune microenvironment and immunotherapy of brain metastasis in non-small cell lung cancer].[非小细胞肺癌脑转移免疫微环境与免疫治疗的研究进展]
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Jan 12;46(1):86-90. doi: 10.3760/cma.j.cn112147-20221101-00863.
4
The Immune Microenvironment in Brain Metastases of Non-Small Cell Lung Cancer.非小细胞肺癌脑转移中的免疫微环境
Front Oncol. 2021 Jul 14;11:698844. doi: 10.3389/fonc.2021.698844. eCollection 2021.
5
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.转移部位在预测接受免疫治疗的癌症患者预后中的不可知作用。
Vaccines (Basel). 2020 Apr 28;8(2):203. doi: 10.3390/vaccines8020203.
6
Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases.晚期非小细胞肺癌肝转移的微环境与免疫治疗研究进展
Front Oncol. 2022 Jul 28;12:893716. doi: 10.3389/fonc.2022.893716. eCollection 2022.
7
Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).脑转移非小细胞肺癌中的免疫抑制微环境:脑转移灶与配对原发性肺肿瘤(GASTO 1060)的全面免疫微环境分析。
Oncoimmunology. 2022 Mar 31;11(1):2059874. doi: 10.1080/2162402X.2022.2059874. eCollection 2022.
8
[Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC].[与非小细胞肺癌脑转移免疫治疗相关的肿瘤微环境基础]
Zhongguo Fei Ai Za Zhi. 2019 Aug 20;22(8):512-519. doi: 10.3779/j.issn.1009-3419.2019.08.06.
9
[Research Progress of Immunotherapy for Brain Metastases in Patients 
with Drive Gene Negative NSCLC].[驱动基因阴性非小细胞肺癌患者脑转移免疫治疗的研究进展]
Zhongguo Fei Ai Za Zhi. 2018 Aug 20;21(8):610-614. doi: 10.3779/j.issn.1009-3419.2018.08.06.
10
Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC.非小细胞肺癌患者原发性肿瘤与脑转移瘤之间肿瘤微环境的比较
JTO Clin Res Rep. 2021 Sep 20;2(10):100230. doi: 10.1016/j.jtocrr.2021.100230. eCollection 2021 Oct.

引用本文的文献

1
Research progress of anti-angiogenic therapy combined with immunotherapy and radiotherapy for the treatment of brain metastases in non-small cell lung cancer (Review).抗血管生成疗法联合免疫疗法及放射疗法治疗非小细胞肺癌脑转移的研究进展(综述)
Oncol Lett. 2025 Jul 8;30(3):434. doi: 10.3892/ol.2025.15180. eCollection 2025 Sep.
2
Directional interactions from non-small cell lung cancer to brain glucose metabolism revealed by total-body PET imaging.全身PET成像揭示非小细胞肺癌与脑葡萄糖代谢之间的定向相互作用。
Eur J Nucl Med Mol Imaging. 2025 May 9. doi: 10.1007/s00259-025-07324-w.
3
Developing a predictive model and uncovering immune influences on prognosis for brain metastasis from lung carcinomas.

本文引用的文献

1
The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis.非小细胞肺癌脑转移的空间转录组图谱。
Nat Commun. 2022 Oct 10;13(1):5983. doi: 10.1038/s41467-022-33365-y.
2
Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer.脑转移非小细胞肺癌的肿瘤免疫微环境与免疫治疗
Front Immunol. 2022 Feb 17;13:829451. doi: 10.3389/fimmu.2022.829451. eCollection 2022.
3
Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.
建立预测模型并揭示免疫因素对肺癌脑转移预后的影响。
Front Oncol. 2025 Mar 3;15:1554242. doi: 10.3389/fonc.2025.1554242. eCollection 2025.
4
Immunotherapy and PD-L1 Tumor Expression in Moroccan Non-Small Cell Lung Cancer Patients with Various Metastasis.免疫疗法与 PD-L1 肿瘤表达在有不同转移的摩洛哥非小细胞肺癌患者中的应用。
Asian Pac J Cancer Prev. 2024 Aug 1;25(8):2841-2852. doi: 10.31557/APJCP.2024.25.8.2841.
5
Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers.放疗对肿瘤微环境的双重影响及其在胃肠道和胸段癌症中对免疫治疗耐药性发展的作用。
Front Cell Dev Biol. 2023 Oct 3;11:1266537. doi: 10.3389/fcell.2023.1266537. eCollection 2023.
曲妥珠单抗联合神经干细胞分泌抗 HER2 抗体延长脑转移癌小鼠的生存期。
Proc Natl Acad Sci U S A. 2022 Jan 4;119(1). doi: 10.1073/pnas.2112491119.
4
Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases.术后立体定向放射外科治疗切除脑转移瘤后伴或不伴免疫治疗的脑膜疾病和脑控制。
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003730.
5
Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis.神经元暴露会在脑转移早期诱导肿瘤中的神经递质信号和突触介质。
Neuro Oncol. 2022 Jun 1;24(6):914-924. doi: 10.1093/neuonc/noab290.
6
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.卡瑞利珠单抗联合卡铂和紫杉醇一线治疗晚期鳞状 NSCLC(CameL-Sq):一项 3 期试验。
J Thorac Oncol. 2022 Apr;17(4):544-557. doi: 10.1016/j.jtho.2021.11.018. Epub 2021 Dec 16.
7
Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance.脑肿瘤中的血脑屏障:生物学及临床相关性
Int J Mol Sci. 2021 Nov 23;22(23):12654. doi: 10.3390/ijms222312654.
8
Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases.肺癌脑转移灶中 T 细胞免疫微环境的空间解析分析。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-002684.
9
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.特泊替尼联合化疗二线治疗 EGFR 突变晚期 NSCLC 患者:一项多中心 II 期试验。
Signal Transduct Target Ther. 2021 Oct 15;6(1):355. doi: 10.1038/s41392-021-00751-9.
10
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.纳武利尤单抗联合伊匹木单抗一线治疗晚期 NSCLC:CheckMate 227 部分 1 期随机、开放标签、3 期临床试验的 4 年结果。
J Thorac Oncol. 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010. Epub 2021 Oct 12.